Evidence map›Paper›PMID 40340749›Full record

ArticleGenome medicine2025

Distinct pathways for genetic and epigenetic predisposition in familial and bilateral Wilms tumor.

Jenny Wegert, Silke Appenzeller, Taryn D Treger, Heike Streitenberger, Barbara Ziegler, Sabrina Bausenwein, Christian Vokuhl, Conor Parks, Eva Jüttner, Susanne Gramlich and 22 more

Abstract read
In one paragraph

Article in Genome medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. [Teratoid Wilms tumor in an adult: A case report].Revista medica del Instituto Mexicano del Seguro Social · 2026
    Article
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Jenny WegertDevelopmental Biochemistry, Theodor-Boveri-Institute/Biocenter, Julius-Maximilians-University Würzburg, Am Hubland, Würzburg, 97074, Germany.
Silke AppenzellerComprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Würzburg, Germany.
Taryn D TregerWellcome Sanger Institute, Hinxton, UK.
Heike StreitenbergerDevelopmental Biochemistry, Theodor-Boveri-Institute/Biocenter, Julius-Maximilians-University Würzburg, Am Hubland, Würzburg, 97074, Germany.
Barbara ZieglerDevelopmental Biochemistry, Theodor-Boveri-Institute/Biocenter, Julius-Maximilians-University Würzburg, Am Hubland, Würzburg, 97074, Germany.
Sabrina BausenweinDevelopmental Biochemistry, Theodor-Boveri-Institute/Biocenter, Julius-Maximilians-University Würzburg, Am Hubland, Würzburg, 97074, Germany.
Christian VokuhlSection of Pediatric Pathology, Department of Pathology, University Hospital Bonn, Bonn, Germany.
Conor ParksWellcome Sanger Institute, Hinxton, UK.
Eva JüttnerDepartment of Pathology, Schleswig-Holstein University Hospital, Kiel, Germany.
Susanne GramlichDepartment of Pathology, University of Würzburg, Würzburg, Germany.
Karen ErnestusDepartment of Pathology, University of Würzburg, Würzburg, Germany.
Steven W WarmanClinic of Pediatric Surgery, Charité - University Hospital Berlin, Berlin, Germany.
Jörg FuchsDepartment of Pediatric Surgery and Pediatric Urology, University Children's Hospital, Tuebingen, Germany.
Jochen HubertusDepartment of Pediatric Surgery, Marien Hospital Witten, Ruhr-University Bochum, Bochum, Germany.
Dietrich von SchweinitzDepartment of Pediatric Surgery, Dr. von Hauner Children's Hospital, LMU University Hospital, Munich, Germany.
Birgit FröhlichDepartment of Pediatric Oncology and Hematology, University of Münster, Münster, Germany.
Norbert JorchEvangelisches Klinikum Bethel, Universitätsklinikum OWL, Bielefeld, Germany.
Ralf KnöflerDepartment of Pediatric Hematology/Oncology, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Carsten FriedrichDepartment of Pediatrics and Pediatric Hematology/Oncology, University Children's Hospital, Carl von Ossietzky University, Klinikum Oldenburg, Oldenburg, Germany.
Selim CorbaciogluChildren's Hospital Regensburg, University of Regensburg, Regensburg, Germany.
Michael C FrühwaldSwabian Children's Cancer Center, Pediatrics and Adolescent Medicine, University Hospital Augsburg, Augsburg, Germany.
Arnulf PekrunPediatric Hematology and Oncology, Klinikum Bremen, Bremen, Germany.
Dominik T SchneiderClinic of Pediatrics, University Witten/Herdecke, Klinikum Dortmund, Witten, Germany.
Jörg FaberDepartment of Pediatric Hematology/Oncology, Center for Pediatric and Adolescent Medicine, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.
Jana StursbergDepartment of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany.
Markus MetzlerDepartment of Pediatrics and Adolescent Medicine, University of Erlangen-Nürnberg, Erlangen, Germany.
Nils WelterDepartment of Pediatric Hematology and Oncology, Saarland University Hospital, Homburg, Germany.
Kathy Pritchard-JonesUCL Great Ormond Street Institute of Child Health, University College London, London, UK.
Norbert GrafDepartment of Pediatric Hematology and Oncology, Saarland University Hospital, Homburg, Germany.
Rhoikos FurtwänglerDepartment of Pediatric Hematology and Oncology, Saarland University Hospital, Homburg, Germany.
Sam BehjatiWellcome Sanger Institute, Hinxton, UK.
Manfred GesslerDevelopmental Biochemistry, Theodor-Boveri-Institute/Biocenter, Julius-Maximilians-University Würzburg, Am Hubland, Würzburg, 97074, Germany. manfred.gessler@uni-wuerzburg.de.

Funding

Deutsche Forschungsgemeinschaft 419964688Deutsche Krebshilfe 50-2709-Gr2Little Princess Trust CCLGA 2019 27Wellcome TrustWellcome Trust 220540/Z/20/A
6 · The paper itself

Abstract

backgroundGenetic predisposition is particularly common in children with the kidney cancer, Wilms tumor. In 10% of these children, this manifests as a family history of Wilms tumor or bilateral disease. The frequency and spectrum of underlying changes have not been systematically investigated.

methodsWe analyzed 129 children with suspected Wilms tumor predisposition, 20 familial cases, and 109 children with bilateral disease, enrolled over 30 years in the German SIOP93-01/GPOH and SIOP2001 studies. We used whole exome, whole genome, and targeted DNA sequencing, together with MLPA and targeted methylation assays on tumor, blood, and normal kidney to determine predisposing changes.

resultsPredisposing variants were identified in 117/129 children, comprising DNA variants (57%) and epigenetic changes (34%). Most children had predisposition variants in genes previously implicated in Wilms tumor: most prominently WT1 (n = 35) and less frequently TRIM28, REST, DIS3L2, CTR9, DICER1, CDC73, and NONO. Nine children carried germline mutations in cancer predisposition genes not considered Wilms tumor predisposition genes, such as CHEK2, CDKN2A, BLM, BRCA2, STK11, and FMN2. Predisposition via epigenetic BWS-IC1 alterations occurred as early somatic events, reflected by partial (mosaic) loss of imprinting or loss of heterozygosity at the IGF2/H19 locus in normal kidney or blood. These patients rarely had a clinical diagnosis of Beckwith-Wiedemann syndrome (BWS). Especially WT1-driven tumors follow a stereotypical pathway of germline WT1 mutations becoming homozygous in renal precursor lesions through 11p LOH, which concomitantly activates imprinted IGF2 expression, with subsequent WNT pathway activation leading to tumor growth. There is a high rate of multicentric tumors, which may have previously been missed in unilateral tumors. While Wilms tumor predisposition genes relied on somatic inactivation of the second allele, this was different for general cancer predisposition genes. The latter cases were often associated with additional oncogenic alterations, similar to tumors with epigenetic predisposition.

conclusionsWe identified two main mechanisms of Wilms tumor predisposition: either germline genetic alterations of Wilms tumor and, less frequently, general cancer genes; or postzygotic mosaic imprinting defects activating IGF2. These findings inform future genetic screening and risk assessment of affected children and lend support to liquid biopsy screening for enhanced therapeutic stratification.

Indexed as

Epigenesis, GeneticGenetic Predisposition to DiseaseKidney NeoplasmsWilms TumorChildChild, PreschoolDNA MethylationFemaleGerm-Line MutationHumansInfantMaleBWSCancer predispositionGenomic imprintingHereditary cancerMulticentric tumorsNephroblastomaPediatric cancerWilms tumorWT1

Identifiers

PMID40340749
PMCPMC12060375

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.